(407) AI and Human Based Design of High-Complexity Nano-Therapies for KRAS-Driven Cancer

KRAS-mutated cancers are characterized by aggressive progression, heterogeneity, and resistance to therapy. While multi-drug combinations offer synergistic effects, their clinical application is often hindered by instability, incompatibility, and toxicity. R595, an Iodolium-based ultra-stabilizer, enables the formulation of stable, multi-drug nanoparticles. This study compares two distinct approaches: traditional human-driven decision-making, based on clinical and laboratory data, versus AI-driven optimization and refinement of drug combinations and administration.